Table 3. Frequencies of candidate CNVs in the validation set I by qPCR.
| Position | Gene Symbol | Frequencya | |
|---|---|---|---|
| Amplification | Nonamplification | ||
| chr1_154919397_154921901 | PBXIP1 | 41 (38.68%) | 65 (61.32%) |
| chr5_209198_257662 | SDHA | 69 (61.61%) | 43 (38.39%) |
| chr5_262301_297746 | PDCD6 | 75 (68.18%) | 35 (21.82%) |
| chr5_482152_508485 | SLC9A3 | 29 (25.44%) | 85 (74.56%) |
| chr5_565873_681306 | CEP72 | 75 (60.98%) | 48 (39.02%) |
| TPPP | 11 (9.65%) | 103 (90.35%) | |
| chr5_843417_023251 | BRD9 | 19 (16.38%) | 97 (83.62%) |
| TRIP13 | 27 (23.68%) | 87 (76.32%) | |
| LOC100506688 | 46 (40.35%) | 68 (59.65%) | |
| chr5_1157300 _1368500 | SLC6A19 | 27 (23.48%) | 88 (76.52%) |
| SLC6A18 | 9 (7.89%) | 105 (92.11%) | |
| TERT | 93 (83.78%) | 18 (16.22%) | |
a
Patients with different copy numbers were divided into the two groups of amplification and nonamplification, which were distinguished by a cut-off point of 2−ΔΔCt as 1.3.